Life Sciences Gets a COVID Booster Shot

Three veterans of the life sciences private equity and M&A market share intel about dramatic changes in the industry. Sean Cunningham from private equity firm GTCR and Adam Lohr and Jamie Hendershot of RSM discuss what’s driving the surging IPO market for biotech companies, how clinical trials have continued apace during COVID, considerations for investing in tool-making companies versus drug developers, and the need for private equity partners to bring more to the table than just money.